Dreher Constantin, Sarria Gustavo R, Miebach Georgia, Weiss Christel, Buergy Daniel, Wojtal Paulina, Tavakoli Anoshirwan A, Krug David, Oppitz Hans, Giordano Frank A, Both Marcus, Lohr Frank, Dunst Jürgen, Blanck Oliver, Boda-Heggemann Judit
Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.
Acta Oncol. 2023 Mar;62(3):281-289. doi: 10.1080/0284186X.2023.2187707. Epub 2023 Apr 5.
Stereotactic body radiotherapy (SBRT) is an effective therapeutic approach in patients with liver metastases. However, long-term changes in hepatic normal tissue have to be taken into account in multimodal treatment regimes. Magnetic-resonance-imaging (MRI) based morphologic liver alterations (MMA) after liver SBRT have been analyzed longitudinally.
57 patients treated with gantry-based or robotic-based SBRT of 69 treatment volumes of liver metastases, who had long-term follow-up (FU) ≥6 months were included in this retrospective analysis. Post-SBRT MMAs were contoured on each contrast-enhanced-T1-weighted (T1w) MRI-sequence. Morphologic/volumetric data of the liver and MMAs were evaluated longitudinally, including the dependency on treatment-related factors of the planning target volume (PTV) and liver.
The median FU time was 1 year [6-48 months]. 66 of 69 treatment volumes developed MMAs (mean 143.8 ± 135.1 ccm at first appearance). 31.8% of MMAs resolved completely during FU. Of the persisting MMAs 82.2%/13.3% decreased/increased in size until last available FU. Morphological characterization of the MMAs at first appearance included 75% hypointense and 25% hyperintense T1w-MRI-based appearances. Hypointense as compared to hyperintense appearance was significantly associated with a higher mean liver dose EQD2 ( = 0.0212) and non-significantly greater MMA size. Variance analysis demonstrated a significant reduction of MMA and total liver volume after SBRT ( < 0.0001). The volume reduction decelerated longitudinally for both MMA ( < 0.0001) and liver size ( = 0.0033). Radiation doses (PTV-BED) were not significantly associated with MMA volume reduction. SBRT of liver metastases with mean liver dose EQD2 > 18 Gy were characterized by greater MMA volumes ( = 0.0826) and steeper MMA reduction gradients during FU than those with EQD2 ≤ 18 Gy ( < 0.0001).
Radiogenic MMAs either completely resolve or usually decrease in volume with pronounced reduction during short-term FU. This course was independent of the MMA's morphological appearance. Further, increased mean liver dose was associated with greater MMA size and a greater gradient of MMA size reduction during FU.
立体定向体部放疗(SBRT)是治疗肝转移瘤患者的一种有效方法。然而,在多模式治疗方案中,必须考虑肝脏正常组织的长期变化。已对肝脏SBRT后基于磁共振成像(MRI)的肝脏形态学改变(MMA)进行了纵向分析。
本回顾性分析纳入了57例接受基于龙门架或机器人的SBRT治疗69个肝转移瘤治疗靶区且长期随访(FU)≥6个月的患者。在每个对比增强T1加权(T1w)MRI序列上勾勒出SBRT后的MMA。对肝脏和MMA的形态学/体积数据进行纵向评估,包括对计划靶区(PTV)和肝脏的治疗相关因素的依赖性。
中位FU时间为1年[6 - 48个月]。69个治疗靶区中有66个出现了MMA(首次出现时平均体积为143.8±135.1立方厘米)。31.8%的MMA在FU期间完全消退。在持续存在的MMA中,82.2%/13.3%的体积在最后一次可用FU时减小/增大。首次出现时MMA的形态学特征包括基于T1w-MRI的75%低信号和25%高信号表现。与高信号表现相比,低信号表现与更高的平均肝脏等效均匀剂量EQD2(=0.0212)显著相关,且MMA大小无显著差异。方差分析显示SBRT后MMA和肝脏总体积显著减小(<0.0001)。MMA(<0.0001)和肝脏大小(=0.0 /span>033)的体积减小在纵向均减缓。辐射剂量(PTV-BED)与MMA体积减小无显著相关性。平均肝脏剂量EQD2>18 Gy的肝转移瘤SBRT的特征是MMA体积更大(=0.0826),且在FU期间MMA减小梯度比EQD2≤18 Gy的更陡(<0.0001)。
放射性MMA要么完全消退,要么通常在短期FU期间体积减小,且减小明显。这个过程与MMA的形态学表现无关。此外,平均肝脏剂量增加与更大的MMA大小以及FU期间MMA大小减小梯度更大相关。